Business, energy, technology, markets and global industry news from Business News Today

HEPLISAV-B

PharmaDeviceNews HEPLISAV-B
Representative image of adult vaccine development, highlighting the shift toward simplified dosing and platform innovation as Sanofi expands its immunization strategy.
Features & Analysis

How Sanofi’s CpG 1018 platform could reshape vaccine formulation in 2026

Sanofi's acquisition of CpG 1018 brings TLR9 adjuvants to the forefront. Explore how this could transform combo vaccines and adult immunization strategies.

Read More
Representative image of adult hepatitis B and shingles vaccines, aligned with Sanofi’s acquisition of Dynavax and its push into global adult immunization markets.
Pharma & Biotech

Why Sanofi’s $2.2bn Dynavax deal is a high-stakes bet on adult vaccines

Sanofi to acquire Dynavax for $2.2B to boost adult vaccines. Find out how HEPLISAV-B and Z-1018 fit into Sanofi’s global immunization strategy.

Read More